CN108752461A - 水溶性膜蛋白及其制备和使用方法 - Google Patents

水溶性膜蛋白及其制备和使用方法 Download PDF

Info

Publication number
CN108752461A
CN108752461A CN201810684571.XA CN201810684571A CN108752461A CN 108752461 A CN108752461 A CN 108752461A CN 201810684571 A CN201810684571 A CN 201810684571A CN 108752461 A CN108752461 A CN 108752461A
Authority
CN
China
Prior art keywords
receptor
water
natural
albumen
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810684571.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·张
A·瑞驰
K·科林
L·T·泰格勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of CN108752461A publication Critical patent/CN108752461A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
CN201810684571.XA 2011-02-23 2012-02-23 水溶性膜蛋白及其制备和使用方法 Pending CN108752461A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161445740P 2011-02-23 2011-02-23
US61/445,740 2011-02-23
CN2012800096906A CN103458915A (zh) 2011-02-23 2012-02-23 水溶性膜蛋白及其制备和使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2012800096906A Division CN103458915A (zh) 2011-02-23 2012-02-23 水溶性膜蛋白及其制备和使用方法

Publications (1)

Publication Number Publication Date
CN108752461A true CN108752461A (zh) 2018-11-06

Family

ID=46721234

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810684571.XA Pending CN108752461A (zh) 2011-02-23 2012-02-23 水溶性膜蛋白及其制备和使用方法
CN2012800096906A Pending CN103458915A (zh) 2011-02-23 2012-02-23 水溶性膜蛋白及其制备和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012800096906A Pending CN103458915A (zh) 2011-02-23 2012-02-23 水溶性膜蛋白及其制备和使用方法

Country Status (14)

Country Link
US (4) US8637452B2 (https=)
EP (1) EP2709647B1 (https=)
JP (1) JP6263773B2 (https=)
KR (1) KR101963914B1 (https=)
CN (2) CN108752461A (https=)
AU (3) AU2012220558A1 (https=)
BR (1) BR112013020969A2 (https=)
CA (1) CA2827187C (https=)
CL (1) CL2013002419A1 (https=)
EA (1) EA201391041A1 (https=)
IL (2) IL227886A0 (https=)
MX (1) MX347038B (https=)
SG (2) SG10201701547VA (https=)
WO (1) WO2012116203A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012220558A1 (en) 2011-02-23 2013-08-22 Massachusetts Institute Of Technology Water soluble membrane proteins and methods for the preparation and use thereof
HK1218858A1 (zh) 2013-03-14 2017-03-17 麻省理工学院 用於长时间持续释放人类抗体的多层可注射自组装肽脚手架水凝胶
US9670264B2 (en) * 2013-04-25 2017-06-06 The Trustees Of The University Of Pennsylvania Water soluble G-protein coupled receptor
EP2989440A4 (en) 2013-04-25 2017-01-04 The Trustees Of The University Of Pennsylvania Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor
WO2015148820A1 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
GB2527286A (en) * 2014-06-11 2015-12-23 Rsr Ltd Glycoprotein hormone receptor mutations
WO2016025781A1 (en) 2014-08-15 2016-02-18 Cornell University Compositions and methods for making water-soluble integral membrane proteins
CN104198689A (zh) * 2014-08-25 2014-12-10 李洁 一种检测g-蛋白耦联受体对缩血管物质反应的方法
CN113929766A (zh) * 2015-02-18 2022-01-14 麻省理工学院 水溶性跨膜蛋白及其制备和使用方法
CN104946674B (zh) * 2015-06-17 2018-05-01 山东大学 一种腺苷三磷酸/双磷酸酶及其编码基因与应用
CN106749602A (zh) * 2016-12-30 2017-05-31 武汉金开瑞生物工程有限公司 一种助表达序列及其在无细胞表达adcy2蛋白中的应用
US11293923B2 (en) * 2017-09-01 2022-04-05 Massachusetts Institute Of Technology S-layer protein 2D lattice coupled detergent-free GPCR bioelectronic interfaces, devices, and methods for the use thereof
WO2019117057A1 (ja) * 2017-12-11 2019-06-20 アステラス製薬株式会社 細胞膜透過性ペプチド
CN108245686B (zh) * 2018-01-15 2019-08-13 中国科学院昆明动物研究所 人grk5基因的用途
WO2021195177A1 (en) * 2020-03-25 2021-09-30 Massachusetts Institute Of Technology Qty fc fusion water soluble receptor proteins
US11401320B2 (en) 2020-03-31 2022-08-02 Massachusetts Institute Of Technology QTY FC fusion receptor proteins
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5548068A (en) * 1990-11-30 1996-08-20 Bio-Technology General Corp. Somatotropins with alterations in the alpha-helix 1 region, and combinations with other mutations
US5739273A (en) * 1992-02-12 1998-04-14 Yale University Transmembrane polypeptide and methods of use
CN1350544A (zh) * 1999-03-11 2002-05-22 格莱风科学公司 可溶性膜蛋白受体结构域的化学合成及应用
EP1765776A1 (de) * 2004-07-14 2007-03-28 Zentaris GmbH Neue tetrahydrocarbazolderivate mit verbesserter biologischer wirkung und verbesserter löslichkeit als liganden für g-protein gekoppelte rezeptoren (gpcr's)
WO2007089899A2 (en) * 2006-02-01 2007-08-09 Oklahoma Medical Research Foundation Water-soluble (g protein)-coupled receptor protein
CN101137668A (zh) * 2005-02-08 2008-03-05 研究发展基金会 与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法
WO2008143910A2 (en) * 2007-05-18 2008-11-27 University Of Massachusetts A strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
US20100249002A1 (en) * 2005-06-30 2010-09-30 Whirlpool S.A. Lubricant oil for a refrigeration machine, lubricant composition and refrigeration machine and system

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US544021A (en) * 1895-08-06 William k
JPH09278793A (ja) * 1996-04-10 1997-10-28 Kinichiro Miura ポリペプチド
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EP1254227A2 (en) 2000-02-11 2002-11-06 Amgen Inc. Fusion receptor from tnf family
US20030143668A1 (en) * 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
WO2004065363A2 (en) 2003-01-21 2004-08-05 The Trustees Of The University Of Pennsylvania Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
ATE555126T1 (de) 2004-08-25 2012-05-15 Janssen Pharmaceutica Nv Relaxin-chimere polypeptide und deren herstellung und anwendung
KR101459789B1 (ko) 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
WO2008068534A2 (en) 2008-03-05 2008-06-12 Heptares Therapeutics Limited Crystal structure of a betal -adremergi c receptor and uses thereof
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2012098413A1 (en) 2011-01-21 2012-07-26 Heptares Therapeutics Limited Mutant g-protein coupled receptor proteins and methods for producing them
AU2012220558A1 (en) 2011-02-23 2013-08-22 Massachusetts Institute Of Technology Water soluble membrane proteins and methods for the preparation and use thereof
WO2012120315A2 (en) 2011-03-10 2012-09-13 Heptares Therapeutics Limited Mutant proteins and methods for producing them
US20130273585A1 (en) 2012-04-11 2013-10-17 Gangagen, Inc. Soluble cytoplasmic expression of heterologous proteins in escherichia coli
WO2015148820A1 (en) 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Water-soluble membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5548068A (en) * 1990-11-30 1996-08-20 Bio-Technology General Corp. Somatotropins with alterations in the alpha-helix 1 region, and combinations with other mutations
US5739273A (en) * 1992-02-12 1998-04-14 Yale University Transmembrane polypeptide and methods of use
CN1350544A (zh) * 1999-03-11 2002-05-22 格莱风科学公司 可溶性膜蛋白受体结构域的化学合成及应用
EP1765776A1 (de) * 2004-07-14 2007-03-28 Zentaris GmbH Neue tetrahydrocarbazolderivate mit verbesserter biologischer wirkung und verbesserter löslichkeit als liganden für g-protein gekoppelte rezeptoren (gpcr's)
CN101137668A (zh) * 2005-02-08 2008-03-05 研究发展基金会 与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法
US20100249002A1 (en) * 2005-06-30 2010-09-30 Whirlpool S.A. Lubricant oil for a refrigeration machine, lubricant composition and refrigeration machine and system
WO2007089899A2 (en) * 2006-02-01 2007-08-09 Oklahoma Medical Research Foundation Water-soluble (g protein)-coupled receptor protein
WO2008143910A2 (en) * 2007-05-18 2008-11-27 University Of Massachusetts A strategy for cloning and expressing the extracellular domains of receptors as soluble proteins

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AVRAM M SLOVIC等: "Computational design of water-soluble analogues of the potassium channel KcsA", 《PROC NATL ACAD SCI U S A》 *
CHRISTOPH J WIENKEN等: "Protein-binding assays in biological liquids using microscale thermophoresis", 《NAT COMMUN.》 *
G.A.PETSKO: "《蛋白质结构与功能》", 30 April 2009, 科学出版社 *
J HESSELGESSER等: "Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity", 《J IMMUNOL》 *
KAMIL KHAFIZOV等: "Ligand specificity of odorant receptors", 《J MOL MODEL》 *
S FIRESTEIN: "How the olfactory system makes sense of scents", 《NATURE》 *
吴国利: "《生物化学》", 30 June 1988, 北京师范大学出版社 *
唐有祺: "《生命的化学 生命过程中重要化学问题研究》", 31 December 1998, 湖南科学技术出版社 *
唐炳华: "《分子生物学》", 31 May 2011, 中国中医药出版社 *
顾全等: "基于伪氨基酸组成的G蛋白偶联受体超家族的识别", 《生物医学工程学杂志》 *

Also Published As

Publication number Publication date
IL261151A (en) 2018-10-31
EA201391041A1 (ru) 2014-04-30
BR112013020969A2 (pt) 2018-07-10
SG192646A1 (en) 2013-09-30
IL227886A0 (en) 2013-09-30
JP6263773B2 (ja) 2018-01-24
EP2709647A4 (en) 2015-01-21
CA2827187C (en) 2019-01-08
US10035837B2 (en) 2018-07-31
EP2709647A1 (en) 2014-03-26
US20120252719A1 (en) 2012-10-04
US9309302B2 (en) 2016-04-12
US8637452B2 (en) 2014-01-28
MX347038B (es) 2017-04-10
EP2709647B1 (en) 2019-08-07
US20140243277A1 (en) 2014-08-28
AU2017261525A1 (en) 2017-12-07
CN103458915A (zh) 2013-12-18
WO2012116203A1 (en) 2012-08-30
KR101963914B1 (ko) 2019-03-29
KR20140027117A (ko) 2014-03-06
US20160264640A1 (en) 2016-09-15
SG10201701547VA (en) 2017-03-30
AU2016201914A1 (en) 2016-04-21
MX2013009715A (es) 2014-02-28
CA2827187A1 (en) 2012-08-30
US20180312562A1 (en) 2018-11-01
CL2013002419A1 (es) 2014-06-06
AU2012220558A1 (en) 2013-08-22
JP2014508763A (ja) 2014-04-10

Similar Documents

Publication Publication Date Title
CN108752461A (zh) 水溶性膜蛋白及其制备和使用方法
Hiroaki et al. Implications of the aquaporin-4 structure on array formation and cell adhesion
Haberman et al. Discovery and development of cyclic peptide inhibitors of CIB1
EP3122767B1 (en) Water-soluble trans-membrane proteins and methods for the preparation and use thereof
JP2025060920A (ja) 水溶性膜貫通タンパク質ならびにその調製および使用方法
CN103923195B (zh) 修饰型生物素结合蛋白
RU2014132706A (ru) Нуклеиновые кислоты, специфически связывающие cgrp
JP2002507892A (ja) ヒト・アデニル酸シクラーゼのクローニングおよび特性評価
CN105017410B (zh) 一种b区部分缺失型重组人凝血因子ⅷ
US20180118806A1 (en) Engineered replacement of partial variant water soluble membrane proteins
CN111097037A (zh) 一种psd95-pdz1/2结构域抑制剂及其应用
CN114940715B (zh) 一种能降解新冠病毒n蛋白的短肽及其应用
JP2002514926A (ja) ヒト・アデニル酸シクラーゼのクローニングおよび特性評価
CN112442496B (zh) 精氨酸脱亚胺酶突变体及其应用
CN112359034A (zh) 一种多肽抑制剂及其用途
HK1194294B (en) Water soluble membrane proteins and methods for the preparation and use thereof
HK1194294A (en) Water soluble membrane proteins and methods for the preparation and use thereof
Schafer Extending the HECT Domain of HERC4 Improves Solubility and Catalysis
Hsuan et al. [31] Affinity purification of active epidermal growth factor receptor using monoclonal antibodies
De Poli et al. Thioamides as CD and NMR Reporters of Helical Screw-Sense
Jin Identification and characterization of a novel class of receptor for encephalomyocarditis virus on human cells
Mitakidis Structural studies of cell surface signalling molecules for neuronal guidance and connectivity
Krishna et al. BIOT 1 Investigation of the use of FACS in cell line development

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181106

WD01 Invention patent application deemed withdrawn after publication